REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
Carie Health is a mobile healthcare solution that allows members to connect with a...
Carie Health is a mobile healthcare solution th...
Kodiak Sciences is a clinical stage company developing innovative therapeutics to ...
Kodiak Sciences is a clinical stage company dev...
SINTX Technologies is an OEM ceramics company that develops and commercializes sil...
SINTX Technologies is an OEM ceramics company t...
Unlimited Tomorrow is here to change the way we think about artificial limbs. They...
Unlimited Tomorrow is here to change the way we...
Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...
Exact Sciences Corp. (NASDAQ: EXAS) is committe...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Join the National Investor Network and get the latest information with your interests in mind.